BMS expands biologics facility in MA

By Melissa Fassbender

- Last updated on GMT

Bristol-Myers Squibb has completed an expansion at its Devens, MA, biologics facility. (Photo: Business Wire)
Bristol-Myers Squibb has completed an expansion at its Devens, MA, biologics facility. (Photo: Business Wire)

Related tags Medicine

Bristol-Myers Squibb (BMS) has completed an expansion of its Devens, MA-based biologics facility to support the company’s growing biologics medicines portfolio.

The $280m project increases the site’s workforce by around 200 and adds two new buildings to the 89-acre campus. The expansion project brings the company’s total investment in the site to more than $1bn.

The new facilities add approximately 200,000 square feet in space, and will include a Biologics Development Building for designing processes for investigational medicines’ early production, and a Clinical Manufacturing Building where the medicines will be produced to support clinical trials.

This project represents a significant expansion in the site’s size and mission​,” said Greg Guyer, senior vice president, Biologics Development and Operations.

According to the company, both are new capabilities for the campus, which previously focused on large-scale, bulk biologics manufacturing.

Biologics are increasingly important in the treatment of serious diseases and a rapidly growing part of our company’s pipeline of potential new therapies​,” said Lou Schmukler, president, Global Manufacturing & Supply. “Bringing together biologics development and clinical and commercial manufacturing on one campus will help accelerate the development of these innovative medicines for patients worldwide​.” 

Related topics Bio Developments Facilities

Related news

Show more

Related products

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us

Products

View more

Webinars